7 results
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
5 Sep 23
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
8:36am
closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. In connection
8-K
MIRM
Mirum Pharmaceuticals Inc
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
) the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 … through April 16, 2024 to satisfy antitrust conditions, the Asset Purchase is not consummated by October 16, 2023.
The foregoing description
8-K
EX-2.1
MIRM
Mirum Pharmaceuticals Inc
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
in such calendar year.
“Antitrust Laws” means the Sherman Act, the Clayton Act, the HSR Act, the Federal Trade Commission Act, state antitrust Laws and all … ”); or (e) regulatory body, including the FDA and the DEA.
“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
“Immediate Family
8-K
MIRM
Mirum Pharmaceuticals Inc
22 Dec 21
Completion of Acquisition or Disposition of Assets
4:05pm
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, on December 20, 2021, Mirum Pharmaceuticals, Inc. (the “Company
8-K
4ttn5c p8u96
19 Nov 21
Entry into a Material Definitive Agreement
6:08am
8-K
EX-10.1
lr8iq1ng42ut9t4gmn7
19 Nov 21
Entry into a Material Definitive Agreement
6:08am
- Prev
- 1
- Next